In a phase I clinical trial (NCT02892123), zanidatamab demonstrated preliminary antitumor activity and had a tolerable safety profile when used alone or with chemotherapy in patients with pre-treated advanced HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.